Contraception Language in Informed Consent Forms: A Survey of Biopharmaceutical Companies

被引:0
作者
Eric W. Ng
Padmaja Chiruvolu
Gweneth F. Levy
Brent R. Allan
Diego F. Wyszynski
机构
[1] Amgen Inc,Maternal and Pediatric Safety
[2] Amgen Inc,Biostatistics
[3] Amgen Inc,Medical Safety Review Team
[4] Medical Assessment Safety Team Amgen Inc,undefined
[5] One Amgen Center Drive MS 17-1-A,undefined
来源
Drug information journal : DIJ / Drug Information Association | 2012年 / 46卷
关键词
clinical trial; contraception; drug industry; informed consent; pregnancy;
D O I
暂无
中图分类号
学科分类号
摘要
Although contraception language is typically required in subject informed consent forms (ICFs) used in clinical trials, there are no regulatory guidelines on the type and duration of methods of contraception that should be used. The authors conducted an anonymous 3-part survey to assess what contraception language biopharmaceutical companies use in their ICFs as well as the staff composition of the companies’ pharmacovigilance teams dealing with pregnancy and lactation. The majority of the companies sponsor clinical trials involving either small molecules (drugs) or a mix of small and large (biologics) molecules. The survey showed notably different answers between companies. Also, only a few companies have staff specifically dedicated to overseeing the enrollment of women of childbearing potential and following their progress if they become pregnant. The findings from this survey indicate that there is little uniformity among biopharmaceutical companies with respect to the contraception language included in ICFs.
引用
收藏
页码:329 / 335
页数:6
相关论文
共 20 条
  • [1] Nolan MT(1999)Consent documents, reproductive issues, and the inclusion of women in clinical trials Acad Med 74 275-281
  • [2] Pressman EK(2000)Contraceptive requirements for clinical research Obstet Gynecol 95 861-866
  • [3] Starklauf BL(1996)Paternal exposures: impact on reproductive and developmental outcome: an overview Pharmacol Biochem Behav 55 691-700
  • [4] Cain J(1999)Teratogen update: paternal exposures-reproductive risks Teratology 60 161-172
  • [5] Lowell J(2008)Paternal exposure and counselling: experience of a Teratology Information Service Reprod Toxicol 26 42-46
  • [6] Thorndyke L(2005)The transport of chemicals in semen Birth Defects Res B Dev Reprod Toxicol 74 119-131
  • [7] Friedler G(2006)The ethics of excluding women who become pregnant while participating in clinical trials of anti-epileptic medications Seizure 15 563-570
  • [8] Trasler JM(2006)Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 Perspect Sex Reprod Health 38 90-96
  • [9] Doerksen T(2004)Complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials J Womens Health (Larchmt) 13 743-744
  • [10] De Santis M(undefined)undefined undefined undefined undefined-undefined